Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. حسب William C. Barley (8915282)

الموضوعات:

Effects of finerenone on the urinary β2-MG levels in all patients. حسب Jia Song (495396)

الموضوعات:

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. حسب Hakim Ben Abdallah (14578241)

Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. حسب Michael J. Johnson (5818168)

"…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…"

TH5487 decreases RSV-induced release of lactose dehydrogenase (LDH). حسب Lang Pan (5145221)

GLS inhibition decreases IL-1β secretion <i>in vitro</i>. حسب Bárbara Ponzilacqua-Silva (17002156)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

Effects of BM-MSCs on ROS generation in DCS rats. حسب Chen Lu (135200)

الموضوعات:

Summary of post-treatment disease course measures from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات:

Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical efficacy of relevant PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات: